These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 33222559

  • 1. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, Watts SD, Chen YF, Simpson EL, Silverberg JI.
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [Abstract] [Full Text] [Related]

  • 2. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K.
    JAMA Dermatol; 2021 Jun 01; 157(6):691-699. PubMed ID: 33978711
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, Ghislain PD, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K, BREEZE-AD4 study group.
    Br J Dermatol; 2022 Sep 01; 187(3):338-352. PubMed ID: 35484697
    [Abstract] [Full Text] [Related]

  • 4. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
    Masuda K, Delozier AM, Kolodsick J, Buchanan A, Pink AE, Sun L, Wang Z, Stingeni L, Thac I D.
    Eur J Dermatol; 2022 Apr 01; 32(2):237-243. PubMed ID: 35866910
    [Abstract] [Full Text] [Related]

  • 5. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
    Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K.
    Br J Dermatol; 2020 Aug 01; 183(2):242-255. PubMed ID: 31995838
    [Abstract] [Full Text] [Related]

  • 6. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
    Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Peñas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M.
    Dermatol Ther (Heidelb); 2021 Jun 01; 11(3):971-982. PubMed ID: 33899152
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
    Thyssen JP, Buhl T, Fernández-Peñas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Ständer S.
    Dermatol Ther (Heidelb); 2021 Oct 01; 11(5):1599-1611. PubMed ID: 34275122
    [Abstract] [Full Text] [Related]

  • 11. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D, Fretzin S, Strowd L, Casillas M, DeLozier AM, Dawson Z, Chen S, Lu N, Thyssen JP.
    J Cutan Med Surg; 2022 Oct 01; 26(4):377-385. PubMed ID: 35354410
    [Abstract] [Full Text] [Related]

  • 12. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
    Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, Silverberg JI, Rueda MJ, DeLozier AM, Pierce E, Yang FE, Sun L, Ball S, Tauber M, Paul C.
    J Eur Acad Dermatol Venereol; 2021 Jul 01; 35(7):1543-1552. PubMed ID: 33834521
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
    Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, Zhu D, Pontes Filho MAG, Wu WS, Eichenfield LF.
    Br J Dermatol; 2023 Jul 07; 189(1):23-32. PubMed ID: 36999560
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
    Lio PA, Simpson EL, Han G, Soung J, Ball S, Sun L, Casillas M, DeLozier AM, Ding Y, Eichenfield LF.
    J Dermatolog Treat; 2022 Jun 07; 33(4):2057-2062. PubMed ID: 34176407
    [Abstract] [Full Text] [Related]

  • 17. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
    Thyssen JP, Werfel T, Barbarot S, Hunter HJA, Pierce E, Sun L, Cirri L, Buchanan AS, Lu N, Wollenberg A.
    J Dermatolog Treat; 2023 Dec 07; 34(1):2190430. PubMed ID: 36912484
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL.
    JAMA Dermatol; 2020 Dec 01; 156(12):1333-1343. PubMed ID: 33001140
    [Abstract] [Full Text] [Related]

  • 19. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
    Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, Guttman-Yassky E, Marnell D, Bissonnette R, Waibel J, Nunes FP, DeLozier AM, Angle R, Gamalo M, Holzwarth K, Goldblum O, Zhong J, Janes J, Papp K.
    J Am Acad Dermatol; 2021 Jul 01; 85(1):62-70. PubMed ID: 33600915
    [Abstract] [Full Text] [Related]

  • 20. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
    Wollenberg A, Lio P, Kleyn E, Bissonnette R, Jose Rueda M, Casillas M, Chen YF, Lu N, Schloebe A, Simpson E.
    Eur J Dermatol; 2022 Jul 01; 32(4):522-529. PubMed ID: 36301752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.